Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Matthew Hatcher via Getty Images

Pfizer and BioNTech asked the Food and Drug Administration Friday to expand the emergency use authorization of its COVID vaccine to cover adolescents ages 12–15.

Why it matters: The authorization would broaden vaccination efforts and speed up the country's race to herd immunity, a goal that will ultimately require teenagers and children to be vaccinated as well.

The big picture: A trial of more than 2,200 children between the ages of 12 and 15 found that the Pfizer/BioNTech vaccine was 100% effective at protecting against the coronavirus.

  • "Across the globe, we are longing for a normal life. This is especially true for our children," Ugur Sahin, CEO and co-founder of BioNTech, said in March.
  • Pfizer and BioNTech announced last month that the first doses were administered in a trial for children ages 6 months to 11 years.

Go deeper: The pandemic's toll on teens

Go deeper

Caitlin Owens, author of Vitals
Apr 9, 2021 - Health

America may be close to hitting a vaccine wall

Data: CDC; Cartogram: Andrew Witherspoon/Axios

There are growing signs that parts of the country may be close to meeting demand for the coronavirus vaccine — well before the U.S. has reached herd immunity.

Why it matters: For the last few months, the primary focus of the U.S. has been getting shots to everyone who wants them, as quickly as possible. Soon, that focus will abruptly shift to convincing holdouts to get vaccinated.

Apr 9, 2021 - Health

CDC says Johnson & Johnson vaccine supply will drop 80% next week

Photo: Niels Wenstedt/BSR Agency via Getty Images

Allocations of Johnson & Johnson's coronavirus vaccine will plummet by 80% next week, according to data released by the Centers for Disease and Control Prevention.

Why it matters: J&J's single-dose shot is viewed as key to U.S. efforts to vaccinate enough Americans to reach herd immunity as soon as possible. A spokesperson told the Wall Street Journal that J&J is still aiming to meet its goal of delivering 100 million doses by June.